The lipid layer of HF158K1 incorporates a new excipient, TL01, which contains a Fab fragment of trastuzumab bound to PEG-DSPE, which can act as a targeting ligand of human epidermal growth factor receptor 2 (HER-2). Preclinical studies have shown that HF158K1 can bind to and be internalized by tumor cells expressing HER-2. The anti-cancer cell activities improved 10-100 times, and it could also be effective on doxorubicin-resistant cancer cells.~HF158K1 is superior to traditional doxorubicin liposomes in terms of antitumor efficacy, and superior to Doxil and Kadcyla in terms of the antitumor treatment of HER-2-positive tumors and triple-negative breast cancer animal models, indicating that HF158K1 is an innovative antitumor drug with great clinical potential
HF158K1 is a modified targeted doxorubicin liposome injection for the treatment of HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors. HF158K1 was developed and optimized based on Doxil, aiming to further improve antitumor efficacy while reducing adverse effects.